Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 2
Submit an article Journal homepage
1,756
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis

Jia-Ning Zhanga The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China;b Changzheng Hospital, Second Military Medical University, Shanghai, ChinaView further author information
,
Feng Weib Changzheng Hospital, Second Military Medical University, Shanghai, ChinaView further author information
,
Lin-Han Leic Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaView further author information
,
Yang Yangd The Sixth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, ChinaView further author information
,
Yuan Yanga The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaCorrespondence[email protected]
View further author information
&
Wei-Ping Zhoua The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaCorrespondence[email protected]
View further author information
Pages 11728-11739 | Received 21 Jun 2021, Accepted 12 Nov 2021, Published online: 12 Dec 2021

References

  • Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer.2020 Jan;1873(1):188314.
  • Orcutt ST, Anaya DA, Orcutt ST, et al. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control J Moffitt Cancer Center. 2018;25(1):1073274817744621.
  • Tang ZY. New thoughts are needed for the study of liver cancer recurrence and metastasis. Zhonghua Gan Zang Bing Za Zhi. 2016;24(5):321–323.
  • Chen JC, Chen MS. [Multidisciplinary therapeutic strategies for recurrence and metastasis of liver cancer]. Zhonghua Gan Zang Bing Za Zhi. 2016;24(5):327–329.
  • Tsim NC, Frampton AE, Habib NA, et al. Surgical treatment for liver cancer. World J Gastroenterol. 2010;16(8):927–933.
  • Wang Z, Jensen MA, Zenklusen JC. A practical guide to The Cancer Genome Atlas (TCGA). New York: Springer; 2016.
  • Deng M, Br?Gelmann J, JL S, et al. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinf. 2016;17(1):72.
  • Xin L, Li MW, Zhang YN, et al. Common cancer genetic analysis methods and application study based on TCGA database. Hereditas (Beijing). 2019;41(3):234–242.
  • Chen L, Wang X, Cheng H, et al. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling. Biochem Biophys Res Commun. 2020;533(4):1162–1169.
  • Bonelli M, Monica SL, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immunomodulation. Biochem Pharmacol. 2019;170:113676.
  • Knudsen ES, Pruitt SC, Hershberger PA, et al. Beyond: exploiting New RB1 controlled mechanisms for cancer therapy - scienceDirect. Trends Cancer. 2019;5(5):308–324.
  • Aarts M, Linardopoulos S, Turner NC. Tumour selective targeting of cell cycle kinases for cancer treatment. Curr Opin Pharmacol. 2013;13(4):529–535.
  • Jie S, Zhang H, Jing Y, et al. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2. Cancer Lett. 2020;469:22–34.
  • Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol. 2019 Mar-Apr;9(2):245-256. .
  • Balogh J, Victor D, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53.
  • Roskilly A, Rowe IA. Surveillance for hepatocellular cancer. Clin Med. 2018;18(Suppl 2):s66–s9.
  • Han TS, Ban HS, Hur K, et al. The epigenetic regulation of HCC metastasis. Int J Mol Sci. 2018;19:12.
  • Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1(1):2–14.
  • Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer. 2012;1(3–4):144–158.
  • Wang J, Yang T, Chen H, et al. RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway. Biochem Biophys Res Commun. 2018;498(3):424–430.
  • Wang H, Liao P, Zeng SX, et al. Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells. Cancer Biol Ther. 2019;21(3):1–9.
  • Sonia P, Tolaney SM, Winer EP, et al. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018;10:175883591878645.
  • Neil P, Sarah A, Emma C, et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer. 2019;26(1):R15–R30.
  • Qyc A, Zhk A, Nlcb A, et al. A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib. Pharmacol Res;2020 Jun;156:104686. .
  • Pan Q, Sathe A, Black PC, et al. CDK4/6 Inhibitors in Cancer Therapy: aNovel Treatement Strategy for Bladder Cancer. Bladder Cancer. 2017;3(2):79–88.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.